Venclyxto in combination with obinutuzumab is indicated for the
treatment of adult patients with previously untreated chronic
lymphocytic leukaemia (CLL).
Venclyxto in combination with
rituximab is indicated for the treatment of adult patients with
CLL who have received at least one prior therapy.
Venclyxto monotherapy is
indicated for the treatment of CLL:
• in the presence of *7p deletion
or TP*3 mutation in adult patients who are
unsuitable for or have failed a B-cell receptor pathway
inhibitor,
• in the absence of *7p deletion
or TP*3 mutation in adult patients who have
failed both chemoimmunotherapy and a B-cell receptor pathway
inhibitor.
| 国家: | Turkey |
| 型号: | - |
| 离岸价格: | 获取最新报价 |
| 位置: | - |
| 最小订单价格: | - |
| 最小订单: | - |
| 包装细节: | - |
| 交货时间: | - |
| 供应能力: | - |
| 付款方式: | - |
| 產品組 : | - |
